Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
2024年5月13日 - 9:30PM
ビジネスワイヤ(英語)
Ensoma, a genomic medicines company advancing the future of
medicine through precision one-time, in vivo treatments that
precisely engineer any cell of the hematopoietic system, today
announced the appointment of Jim Burns, Ph.D., as chief executive
officer and a member of the company’s board of directors.
“Jim Burns is an accomplished biotechnology executive who joins
Ensoma at a critical and exciting time for the company as we
advance our first program through IND-enabling studies,” said Paula
Soteropoulos, chairman of the board and interim CEO of Ensoma.
“Jim’s track record of leadership and groundbreaking work in
product development, notably as CEO of Locanabio, where he
spearheaded the development of RNA-targeted gene therapies, and
Casebia Therapeutics, a pioneer in CRISPR/Cas9-based therapeutics,
aligns with Ensoma's mission to advance precision genomic medicines
through innovative technologies.”
“I am excited to join Ensoma’s highly talented team that is
quickly advancing the next wave of genetic medicines in which
hematopoietic stem cells are genetically engineered in vivo to
treat disease with a single off-the-shelf therapeutic
administration,” said Dr. Burns. “This approach holds tremendous
promise for patients in need. I am committed to accelerating our
first program toward the clinic, while further expanding our
efforts to address a range of devastating genetic, immunological
and oncological conditions, bringing the possibility of
life-changing treatments to individuals and families
worldwide.”
Prior to joining Ensoma, Dr. Burns was CEO of Locanabio, a
company focused on developing genetic medicines for neuromuscular
and neurodegenerative diseases. Before that, he was CEO of Casebia
Therapeutics, which is now part of CRISPR Therapeutics. Dr. Burns
spent the bulk of his career at Genzyme and Sanofi, where he held
several leadership roles with increasing responsibility, including
North America site head for R&D, where he coordinated R&D
operations across key therapeutic areas. Dr. Burns is a member of
the U.S. National Academy of Engineering and a past board member of
MassBio and the Alliance for Regenerative Medicine.
Dr. Burns earned a Bachelor of Science degree in biology from
Purdue University and Master of Science and doctorate degrees in
bioengineering from the University of Illinois-Chicago, where his
thesis work focused on drug delivery. Following his graduate
studies, he was a postdoctoral researcher at the University of
Florida.
About Ensoma
Ensoma is developing curative medicines through precision in
vivo cellular engineering. Our Engenious™ platform combines
class-leading proprietary base editing and high-efficiency gene
integration systems with high-capacity virus-like particles to
provide one-time and durable genetic medicines in a simple
outpatient procedure. We are focused on in vivo engineering of
hematopoietic stem cells to address genetic diseases, immune
disorders and oncology. Ensoma is supported by top-tier investors
and a passionate team committed to a bold, global vision for gene
therapy. Ensoma is based in Boston. For more information, visit
ensoma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513134892/en/
Katie Engleman, 1AB katie@1abmedia.com